This is a working overview of heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-29 and is reviewed periodically as new material appears.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Jaundice Abnormal liver function test results Tardive dyskinesia – an often incurable movement disorder that usually results from years of continuous treatment with antipsychotic drugs, especially typical antipsychotics like flupenthixol. It presents with repetitive, involuntary, purposeless and slow movements; TD can be triggered by a fast dose reduction in any antipsychotic. Hypotension Confusional state Seizures Mania Hypomania Depression Hot flush Anergia Appetite changes Weight changes Hyperglycemia – high blood glucose (sugar) levels Abnormal glucose tolerance Pruritus – itchiness Rash Dermatitis Photosensitivity – sensitivity to light Oculogyric crisis Accommodation disorder Sleep disorder Impaired concentration Tachycardia QTc interval prolongation – an abnormality in the electrical activity of the heart that can lead to potentially fatal changes in heart rhythm (only in overdose or <10 ms increases in QTc) Torsades de pointes Miosis – constriction of the pupil of the eye Paralytic ileus – paralysis of the bowel muscles leading to severe constipation, inability to pass wind, etc. Mydriasis Glaucoma
Pholcodine is an opioid cough suppressant (antitussive). It helps suppress unproductive coughs and also has a mild sedative effect, but has little or no analgesic effects. It is also known as morpholinylethylmorphine and homocodeine. Pholcodine is found in certain cough lozenges, and more commonly as an oral solution, typically 5 mg / 5 ml. Adult dosage is 5-10 ml up to 3-4 times daily. Pholcodine now largely replaces the previously more common codeine linctus, as it has a much lower potential for dependence. Pholcodine has been widely used as an antitussive agent but by 2023 concerns over its association with anaphylaxis in some circumstances meant that it has been withdrawn from sale in many territories. Pholcodine is not prescribed in the United States where it is classed as a Schedule I drug, the most highly controlled drug category. Following the conclusion of a review of post-marketing safety data by the Medicines and Healthcare products Regulatory Agency, all pholcodine-containing medicines were recalled and withdrawn from the UK as a precaution. The available data has demonstrated that pholcodine use, particularly in the twelve months before general anesthesia with NMBAs (neuromuscular blocking agents), is a risk factor for developing an anaphylactic reaction to NMBAs. In December 2022, the European Medicines Agency recommended their withdrawal in the EU. As of February 2023, the Australian Therapeutic Goods Administration canceled the registration of pholcodine.
Resmetirom, a liver-directed thyroid hormone receptor beta-selective agonist, was conditionally approved for medical use in the United States in March 2024 for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced fibrosis. Resmetirom was associated with increased rates of MASH resolution or regression of fibrosis, it also improved lipid levels. In August 2025, the US Food and Drug Administration expanded the indication for semaglutide to include the treatment of metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis (excessive scar tissue in the liver). Semaglutide was associated with MASH resolution in a 72-week trial compared to placebo. The percentage of people with MASH resolution was 32.7% (compared to 16% with placebo). Semaglutide may also cause regression of liver fibrosis to a less severe stage. Another trial showed that 63% of people had complete resolution of MASH, and 36.8% had at least 1 level of regression to a less severe stage of liver fibrosis. Semaglutide was also associated with a 13% weight loss in trials of MASH and improvements of some metabolic factors (such as the hemoglobin A1c (sugar levels)) which are protective in both MASLD and MASH.
=== Priapism === A relatively rare side effect associated with trazodone is priapism, likely due to its antagonism at α-adrenergic receptors. More than 200 cases have been reported, and the manufacturer estimated that the incidence of any abnormal erectile function is about one in 6,000 male patients treated with trazodone. The risk for this side effect appears to be greatest during the first month of treatment at low dosages (i.e. <150 mg/day). Early recognition of any abnormal erectile function is important, including prolonged or inappropriate erections, and should prompt discontinuation of trazodone treatment. Spontaneous orgasms have also been reported with trazodone in men. Clinical reports have described trazodone-associated psychosexual side effects in women as well, including increased libido, priapism of the clitoris, and spontaneous orgasms.
Sources: en.wikipedia.org
The temperature at which the Leidenfrost effect appears is difficult to predict. Even if the volume of the drop of liquid stays the same, the Leidenfrost point may be quite different, with a complicated dependence on the properties of the surface, as well as any impurities in the liquid. Some research has been conducted into a theoretical model of the system, but it is quite complicated. The effect was also described by the Victorian steam boiler designer, William Fairbairn, in reference to its effect on massively reducing heat transfer from a hot iron surface to water, such as within a boiler. In a pair of lectures on boiler design, he cited the work of Pierre Hippolyte Boutigny (1798–1884) and Professor Bowman of King's College, London, in studying this. A drop of water that was vaporized almost immediately at 168 °C (334 °F) persisted for 152 seconds at 202 °C (396 °F). Lower temperatures in a boiler firebox might evaporate water more quickly as a result; compare Mpemba effect. An alternative approach was to increase the temperature beyond the Leidenfrost point. Fairbairn considered this, too, and may have been contemplating the flash steam boiler, but considered the technical aspects insurmountable for the time. The Leidenfrost point may also be taken to be the temperature for which the hovering droplet lasts longest. It has been demonstrated that it is possible to stabilize the Leidenfrost vapor layer of water by exploiting superhydrophobic surfaces.
A music video directed by Adam Mason was released on November 1, 2018, and continued the storyline from the music video of "The One You Know". In June 2018, William DuVall said in an interview with Swedish website Rocksverige that the music video for "The One You Know" is the first chapter of what the band is hoping will be visuals for all ten songs from the album Rainier Fog, and in addition to that, will be a companion piece to the film that director Adam Mason was shooting. On August 20, 2018, the baseball team Seattle Mariners hosted a special "Alice in Chains Night" at the Safeco Field in Seattle to promote Rainier Fog, with the team offering the fans a package that included a Safeco Field terrace club ticket, access to a pre-game listening party of the album, an Alice in Chains T-shirt and a Rainier Fog CD. Jerry Cantrell also threw out the ceremonial first pitch and delivered a strike before the Seattle Mariners vs. Houston Astros game. To mark the launch of the album, on August 21, 2018, Alice in Chains performed an acoustic set at the top of Seattle's Space Needle and debuted the song "Fly". Alice in Chains were the first band to perform on the Space Needle's new "Loupe" glass floor, the world's first and only revolving glass floor 500 feet high. The concert was exclusive for an audience of SiriusXM subscribers. SiriusXM broadcast the concert on their channel Lithium on August 31, 2018.
== Enthalpy change == The enthalpy of sublimation has commonly been predicted using the equipartition theorem. If the lattice energy is assumed to be approximately half the packing energy, then the following thermodynamic corrections can be applied to predict the enthalpy of sublimation. Assuming a 1 molar ideal gas gives a correction for the thermodynamic environment (pressure and volume) in which pV = RT, hence a correction of 1RT. Additional corrections for the vibrations, rotations and translation then need to be applied. From the equipartition theorem gaseous rotation and translation contribute 1.5RT each to the final state, therefore a +3RT correction. Crystalline vibrations and rotations contribute 3RT each to the initial state, hence −6RT. Summing the RT corrections; −6RT + 3RT + RT = −2RT. This leads to the following approximate sublimation enthalpy. A similar approximation can be found for the entropy term if rigid bodies are assumed.
Compounds like amino acid peptides, proteins, nucleotides, nucleic acid, amines, and antibiotics are usually not called alkaloids. Natural compounds containing nitrogen in the exocyclic position (mescaline, serotonin, dopamine, etc.) are usually classified as amines rather than as alkaloids. Some authors, however, consider alkaloids a special case of amines.
== Honors == In 2015, Ariely received an honorary doctorate from Erasmus University Rotterdam. He is also a two-time recipient of the William F. O'Dell Award for articles he co-authored. In 2008, Ariely, along with his co-authors, Rebecca Waber, Ziv Carmon, and Baba Shiv, was awarded an Ig Nobel Prize in medicine for their research demonstrating that "high-priced fake medicine is more effective than low-priced fake medicine".
Sources: en.wikipedia.org
Impaired fasting glycemia or impaired fasting glucose (IFG) refers to a condition in which the fasting blood glucose is elevated above what is considered normal levels but is not high enough to be classified as diabetes mellitus. It is considered a pre-diabetic state, associated with insulin resistance and increased risk of cardiovascular pathology, although of lesser risk than impaired glucose tolerance (IGT). IFG sometimes progresses to type 2 diabetes mellitus. Fasting blood glucose levels are in a continuum within a given population, with higher fasting glucose levels corresponding to a higher risk for complications caused by the high glucose levels. Some patients with impaired fasting glucose also may be diagnosed with impaired glucose tolerance, but many have normal responses to a glucose tolerance test. Fasting glucose is helpful in identifying prediabetes when positive but has a risk of false negatives. World Health Organization (WHO) criteria for impaired fasting glucose differs from the American Diabetes Association (ADA) criteria, because the normal range of glucose is defined differently by each. Fasting plasma glucose levels 100 mg/dL (5.5 mmol/L) and higher have been shown to increase complication rates significantly, however, WHO opted to keep its upper limit of normal at under 110 mg/dL for fear of causing too many people to be diagnosed as having impaired fasting glucose, whereas the ADA lowered the upper limit of normal to a fasting plasma glucose under 100 mg/dL.
=== Plant === In vivo, plant PPOs are expressed as about 64–68 kDa proteins consisting of three domains: a chloroplastic transit peptide (containing a ~4-9 kDa thylakoid signal peptide), a catalytically active domain (~ 37–42 kDa) containing the dinuclear copper center, and a C-terminal domain (~15–19 kDa) shielding the active site.
A seismic metamaterial is a metamaterial that is designed to counteract the adverse effects of seismic waves on artificial structures. Current designs of seismic metamaterials use configurations of boreholes, trees, or proposed underground resonators to act as a large-scale material. Experiments have observed both reflections and bandgap attenuation from artificially induced seismic waves. These are the first experiments to verify that seismic metamaterials can be measured for frequencies below 100 Hz, where damage from Rayleigh waves is the most harmful to artificial structures.
The Fair Work Act 2009 section 357 codifies a civil remedy for misrepresentation that a contract is independent, rather than one of employment. However, compared to international standards, misclassification takes most through approval by the courts themselves. There are five main types of case. First, unpaid internships have been allowed, though in one case the limit was two weeks. Second, single person corporations can be easily established and engaged through a commercial (rather than employment) contract, although in ACE Insurance Ltd v Trifunovski the Federal Court held that insurance agents who were made to contract through corporations were still employees, even though they might hire clerical assistants. Third, labour hire (or agency work) arrangements were held in Building Workers' Industrial Union of Australia v Odco Pty Ltd to enable people to be classified as self-employed in relation to the party they truly work for, so that even a 22 year old backpacker doing menial labour on building sites was classed as self-employed. Even where a labour hire agency is set up as an employer's wholly owned subsidiary to evade rights, courts have held this was lawful. Further, in FWO v Valuair Ltd (No 2) the Federal Court held that Qantas could use its wholly owned subsidiary Jetstar, incorporated in New Zealand, to employ foreign workers to work in Australia on wages lower than Australian staff, undercutting the enterprise agreement.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.